Blog

  • Does Exxon Offer Value After Carbon Capture Plans and a 339% Five Year Rally?

    Does Exxon Offer Value After Carbon Capture Plans and a 339% Five Year Rally?

    Thinking about Exxon Mobil? If you are weighing your next move, you are not alone; the stock is on many investors’ watchlists lately. The past year offers a mixed bag: Exxon is up just 0.1% over twelve months, but a glance at the longer horizon shows a dazzling 339.4% jump over the past five years. Shorter time frames add more texture. The stock boasts a 7.5% gain year-to-date, edging higher by 2.8% in just the last week, and logging a modest 0.7% for the past month. That is a lot of numbers, but they point to a story of potential resilience and changing sentiment.

    Recent headlines have buzzed around Exxon’s ambitious carbon capture plans, further progress in renewable energy investments, and regulatory updates in the energy sector. While these developments have not caused dramatic price swings, they have subtly influenced how the market values Exxon’s future positioning against both traditional oil peers and the new wave of energy transition stocks. For many investors, these signals have shifted perceptions of risk and growth in the sector.

    At a glance, Exxon boasts a strong value score of 4 out of 6, suggesting it is undervalued in most of the key metrics analysts watch. Of course, there is more to the story than numbers alone. In this next section, I will break down the valuation checks in detail, and tease out an even deeper, better way to understand Exxon Mobil’s true value further down the road.

    Why Exxon Mobil is lagging behind its peers

    The Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and then discounting those projections back to today’s dollars. This approach helps investors understand what a business may truly be worth if they held every future dollar the business might generate.

    For Exxon Mobil, the most recent twelve months’ Free Cash Flow stands at approximately $32.4 billion. Looking ahead, analyst estimates suggest steady growth, with projections climbing to $44.7 billion by 2029 and potentially higher through 2035, as extrapolated by Simply Wall St. Analysts supply the first five years of these forecasts, while the later years result from careful modeling based on historical performance and industry outlook.

    Using these projections in the DCF model, Exxon Mobil’s intrinsic value is estimated at $288.47 per share. This is about 60% higher than its current market price, indicating that the stock appears undervalued on a cash-flow basis.

    If these projections materialize, Exxon may present value that is difficult to overlook. For long-term investors, the DCF suggests a significant margin of safety compared to the current share price.

    Continue Reading

  • Nextracker (NXT) Margin Decline Challenges Bullish Narratives Despite Strong Multi-Year Earnings Growth

    Nextracker (NXT) Margin Decline Challenges Bullish Narratives Despite Strong Multi-Year Earnings Growth

    Nextracker (NXT) reported a sharp 58.9% average annual earnings growth over the past five years, though growth moderated to 19.3% in the latest year. Net profit margin edged down slightly to 17.1% from last year’s 17.2%. With revenue forecast to grow at 10.2% per year, just ahead of the US market, while earnings growth is projected at 7.8%, the company trades at a Price-to-Earnings ratio of 25.2x. This is lower than its peers, but with a share price of $98.28 that sits above its estimated fair value of $88.82. Investors are taking note of the company’s strong track record, consistent growth, and high-quality earnings, though expectations have been tempered by shorter-term earnings growth and a premium share price.

    See our full analysis for Nextracker.

    Now, let’s see how these headline numbers stack up next to the narratives widely followed in the market and within the Simply Wall St community.

    See what the community is saying about Nextracker

    NasdaqGS:NXT Earnings & Revenue History as at Oct 2025
    • Nextracker’s record backlog now exceeds $4.5 billion, providing a strong forward-looking buffer as strategic R&D expansion and global partnerships continue to underpin growth potential.

    • Analysts’ consensus view strongly supports the idea that the company’s investment in new R&D facilities across the U.S., Brazil, and India, and high-profile partnerships such as the UC Berkeley collaboration, will reinforce its innovation lead and extend revenue visibility.

      • Sustained demand and a localized supply chain, highlighted by the $4.5 billion backlog, directly counter worries about cyclical slowdowns and offer competitive advantages in retaining market share.

      • The future annual revenue growth forecast of 11.8 percent, just ahead of the broader U.S. market, supports the view that Nextracker’s innovation pipeline is a mainstay for future financial performance rather than a temporary catalyst.

    What stands out in these results is how closely the consensus links innovation investments to future revenue growth and why analyst confidence persists even as some metrics edge lower.
    📊 Read the full Nextracker Consensus Narrative.

    • Net profit margin declined slightly to 17.1 percent this year from 17.2 percent, with consensus expectations predicting a further decrease to 15.3 percent over the next three years as cost and pricing pressures mount.

    • Consensus narrative notes that this expected margin squeeze, despite innovation and revenue momentum, demonstrates how competitive pricing and geographic concentration in the U.S. could test the company’s ability to sustain high profitability.

      • U.S. market dominance exposes Nextracker to downside if policy or demand shifts, particularly because of the anticipated contraction in profit margin and international pricing pressure.

      • Analysts also note that ongoing project complexity and significant R&D spending could challenge net earnings growth unless revenue keeps close pace with new costs.

    Continue Reading

  • Actor June Lockhart of Lost in Space and Lassie fame dies aged 100 | Television

    Actor June Lockhart of Lost in Space and Lassie fame dies aged 100 | Television

    June Lockhart, the popular actor known for her work in film and television, has passed away at the age of 100.

    She died on Thursday night of natural causes, with daughter June Elizabeth and granddaughter Christianna by her side, according to

    Continue Reading

  • Listing dowry articles in ‘Nikah Nama’ part of SC’s family law reforms

    Listing dowry articles in ‘Nikah Nama’ part of SC’s family law reforms

    Apex court proposes stricter penalties for unregistered marriages in its report Redefining Access to Justice 2025

    Police officers walk past the Supreme Court of Pakistan building, in Islamabad, Pakistan April 6, 2022. REUTERS

    Continue Reading

  • George Clooney Wanted Adam Sandler Taken Seriously on ‘Jay Kelly’

    George Clooney Wanted Adam Sandler Taken Seriously on ‘Jay Kelly’

    For their new movie, Jay Kelly, George Clooney had a special rule on set: he didn’t want the cast referring to Adam Sandler by his nickname “Sandman,” in an effort to take the comedian more seriously as an actor.

    At the film’s AFI…

    Continue Reading

  • FAME 3, DOSE Trials Explore Cost-Effectiveness, Operator Radiation Risk After Coronary Procedures

    FAME 3, DOSE Trials Explore Cost-Effectiveness, Operator Radiation Risk After Coronary Procedures

    Interventional cardiology will be in the spotlight during TCT 2025 in San Francisco and amongst the Featured Clinical Research are presentations looking at outcomes in patients following coronary procedures and the risk of radiation for operators.

    A substudy from the randomized FAME 3 trial, simultaneously published in JACC, found that PCI was more cost-effective than CABG in 1,500 patients with three-vessel coronary artery disease, while quality-adjusted life-years were similar at five years in the two groups (4.05 vs. 4.03, respectively). PCI was guided by fractional flow reserve and zotarolimus drug-eluting stents were implanted.

    Researchers reported that cumulative costs over five years were 30% higher in patients randomized to CABG ($36,990 vs. $25,667 for PCI; p<0.001).

    No significant difference was observed for all-cause mortality or for a composite outcome of mortality, myocardial infarction or stroke. More patients who were younger than 65 when they had a CABG vs. PCI were still working at five years (56% vs. 47%).

    “The equal survival rates at five-years in FAME 3 means there was no long-term survival benefit from CABG to justify its substantially higher costs, which is the main reason we found PCI to be the more cost-effective alternative, both at five years and in lifetime projections,” write study investigators Mark A. Hlatky, MD, FACC; Victoria Ding, MS; et al.

    The DOSE study, simultaneously published in JACC: Cardiovascular Interventions, found no significant differences in the amount of radiation exposure of operators who used a strategy of left distal radial access (DRA) vs. right transradial access (TRA) during coronary procedures.

    Conducted at three sites in South Korea, this prospective, open-label trial randomized patients who were undergoing a coronary procedure to DRA (n=501) or right TRA (n=500).

    The radiation dose in the left DRA and right TRA groups was 4.76 vs. 5.20 μSv (p=0.342) measured at the left wrist, 2.00 vs. 1.83 μSv (p=0.416) measured at the head and 1.28 vs. 1.07 μSv (p=0.199) measured at the chest.

    Looking a secondary endpoints, investigators found no significant differences in the incidence of crossover (6.6% vs. 5.2%), fluoroscopy time (4.5 vs. 4.2 min), procedure time (16.0 vs. 15.0 min) or contrast volume (80 Ml for both).

    “The present study is of particular significance in that it provides direct evidence that left DRA does not increase radiation exposure compared to right TRA,” write study authors Oh-Hyun Lee, MD; Ji Woong Roh, MD, PhD, et al. “This finding suggests that radiation hazard should not be considered a limiting factor for the adoption of left DRA in routine clinical practice.”


    Clinical Topics:
    Cardiac Surgery, Cardiovascular Care Team, Invasive Cardiovascular Angiography and Intervention, Atherosclerotic Disease (CAD/PAD), Aortic Surgery, Interventions and Coronary Artery Disease


    Keywords:
    Transcatheter Cardiovascular Therapeutics, TCT25, Drug-Eluting Stents, Fractional Flow Reserve, Myocardial, Coronary Artery Disease, Percutaneous Coronary Intervention, Myocardial Infarction, Stroke, Coronary Artery Bypass

    Continue Reading

  • June Lockhart, beloved mother figure from ‘Lassie’ and ‘Lost In Space,’ dies at 100

    June Lockhart, beloved mother figure from ‘Lassie’ and ‘Lost In Space,’ dies at 100

    LOS ANGELES — June Lockhart, who became a mother figure for a generation of television viewers whether at home in “Lassie” or up in the stratosphere in “Lost In Space,” has died. She was 100.

    Lockhart died Thursday of natural causes at…

    Continue Reading

  • The Blue Jays keep on hitting, and the World Series started with a bang – The Washington Post

    1. The Blue Jays keep on hitting, and the World Series started with a bang  The Washington Post
    2. MLB World Series Game 1: Toronto Blue Jays beat LA Dodgers 11-4  BBC
    3. Blue Jays’ Addison Barger hits the first pinch-hit grand slam in World Series…

    Continue Reading

  • June Lockhart, beloved mother figure from 'Lassie' and 'Lost In Space,' dies at 100 – San Francisco Chronicle

    1. June Lockhart, beloved mother figure from ‘Lassie’ and ‘Lost In Space,’ dies at 100  San Francisco Chronicle
    2. June Lockhart, Beloved Television Mother, Dies at 100  The New York Times
    3. June Lockhart, Beloved Mom on ‘Lassie’ and ‘Lost in…

    Continue Reading

  • Oppo Find X9 Pro: Global import model listed at first retailer with price advantage

    Oppo Find X9 Pro: Global import model listed at first retailer with price advantage

    Our recommendation: Wait for the global launch

    This price includes all taxes, not including shipping costs. However, AverageDad only offers a one-year warranty, and you only have a 14-day right of return if the product has not been opened;…

    Continue Reading